Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The efficacy and safety of toripalimab (JS001) with concurrent chemoradiotherapy in locally advanced squamous cell cervical cancer, a prospective, single arm, single center clinical study

Next Previous
Trial Profile

The efficacy and safety of toripalimab (JS001) with concurrent chemoradiotherapy in locally advanced squamous cell cervical cancer, a prospective, single arm, single center clinical study

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toripalimab (Primary)
  • Indications Carcinoma; Cervical cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRACE

Most Recent Events

  • 03 Oct 2024 Results published in the Cancer Immunology Immunotherapy
  • 07 Jun 2022 Status changed to active, no longer recruiting as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top